Saturday, October 24, 2015

Masimo & Atheer to Demonstrate Prototype of Interactive Root® Iris™ Display Powered by AiR™ Smart Glasses Platform

Demonstrations held at the ASA Anesthesiology 2015 Conference in Masimo Booth 3437 -San Diego Convention Center on October 24-28, 2015

IRVINE, Calif. - Friday, October 23rd 2015 [ME NewsWire]

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) and Atheer announced today that they will unveil a prototype of the Root Iris display App using the Atheer AiR (Augmented interactive Reality) platform and AiR Glasses at the American Society of Anesthesiologists (ASA) annual conference. Demonstrations will be held at Masimo’s Booth 3437 at the San Diego Convention Center on October 24-28, 2015. The demonstrations will allow conference attendees to experience a prototype display and touch-free interactions powered by the Atheer AiR Glasses that, if cleared by the FDA, would provide clinicians with a novel display and interaction experience. Attendees will be invited to provide feedback on features, usability and requirements.

“This is the future of information display and interaction,” said Joe Kiani, Founder and CEO of Masimo. “What was once seen only in the movies is now on the way to becoming a reality. When combined with our Root Iris technology, AiR Glasses may in the future empower anesthesiologists to visualize data from multiple information sources and interact with the data using motion gestures while continuing to care for the patient.”

“We are delighted to partner with Masimo – one of the most innovative medical technology companies in the world. Our AiR smart glasses platform is known for its rich display as well as unique touch-free interaction using gestures, voice and head motion. Now both our companies are leveraging our strengths to develop a novel platform for the medical community,” said Alberto Torres, CEO of Atheer.

Special demonstrations and interviews will be scheduled by appointment for the media. To schedule a media demonstration and interview time, please call 858-859-7001. To obtain a media pass for the Anesthesiology 2015 conference, please email or call 847-268-9106.

@MasimoInnovates | #Masimo | @Atheerlabs | #AiRGlasses

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through-Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at

About Atheer

Atheer is the pioneer of AiR™ (Augmented interactive Reality) computing that is designed to enhance deskless professional productivity. The award-winning Atheer AiR platform combines the power of immersive augmented reality with intelligent gesture, voice and head-motion interaction, all on a mobile, smart glasses platform. Wearing our see-through AiR Glasses, you can view rich information critical to your workflow, interact with the information naturally and collaborate with your remote peers like never before – all while on the move, without the need to hold any device. Leveraging the Atheer AiR platform, developers and companies around the world are creating next generation enterprise productivity applications and workflows to empower the 21st century workforce. For more information, please visit

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.




Irene Paigah, 858-859-7001



Kirsten Maynard, 415-350-4147


No comments:

Post a Comment